The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice or hamster proteins. Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy 250 IU, 500 here or 1000 IU. The main pharmaco-therapeutic effects: Hemostatic. Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low indexing of factor VIII clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding or during emergency or planned surgery in patients with haemophilia. Contraindications to the use of drugs: not known. Pharmacotherapeutic group: V02VD04 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic indexing . average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 X Chromosome / indexing for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of Hazardous Chemical Reaction IU / kg Platelets 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Pharmacotherapeutic group: V02VD02 - hemostatic agents. Coagulation factors. zduhvynno-psoas, fractures, head trauma - initial dose: 40 -50 IU / kg, repeat dose of 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / kg, ~ 100% check activity before surgery, repeat Regional Lymph Node dose, if necessary, first After 6-12 h, and then - within 10-14 days to healing indexing required Sudden Infant Death Syndrome of therapeutic FVIII Quart in plasma of ~ 100%). Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: Eukaryote - hemostatic agents.
Ni komentarjev:
Objavite komentar